Genome Valley (GV), the first of its kind in India, is a state-of-the-art life sciences cluster housing over 200 life science companies. With its conducive ecosystem for research and innovation, GV has become an attractive destination for scientists and researchers worldwide.

Over the years, GV has evolved into a thriving ecosystem not only for vaccine, biotechnology, and pharmaceutical companies but also for full-service Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs), earning its reputation as Asia's premier life sciences hub.

Located strategically in Hyderabad, known as the 'Pharma Capital of India', GV offers seamless access to a vast pharmaceutical and biotech network. This strategic location, combined with support from both the government and private sector, has propelled GV to the forefront of preclinical research in Asia.

This remarkable transformation is fueled by a combination of cutting-edge research, state-of-the-art infrastructure, a skilled talent pool, and strategic collaborations.

Current Preclinical Research Landscape in Genome Valley

GV boasts an impressive array of preclinical CRO that have experienced significant growth over the years. These companies specialise in various aspects of preclinical research, including Drug Metabolism and Pharmacokinetics (DMPK), Pharmacology and Toxicology. Among them, several notable names have emerged as leaders in the field, driving innovation and pushing the boundaries of scientific discovery.

Companies such as Vimta Labs, Syngene, Sai Life Sciences, RCC Laboratories and Eurofins Advinus have established themselves as pioneers in preclinical research services with their groundbreaking methodologies, advanced technologies, and reliable services. These companies offer a full range of preclinical research services both in vitro and in vivo. With a focus on delivering high-quality data and unparalleled expertise, these companies have witnessed remarkable growth and expansion within GV.

Table: Companies in Genome Valley offering Preclinical Research Services

Genome Valley benefits from Hyderabad's prolific life sciences institutes, which churn out a steady stream of skilled technicians and scientists specialized in preclinical research. Institutes such as The Indian Institute of Chemical Technology (IICT), The National Institute of Pharmaceutical Education and Research (NIPER), Centre for Cellular and Molecular Biology (CCMB), The National Institute of Nutrition (NIN) and others produce a talent pool well-versed in the intricacies of preclinical research, ensuring a robust workforce for the region's burgeoning sector.

National Animal Resource Facility for Biomedical Research (NARFBR)

The establishment of a National Animal Resource Facility for Biomedical Research founded in 2015 within GV by the Govt. of India further enhances its capabilities as a leading preclinical research hub. This facility provides researchers with access to a wide range of animal models (rodent, canine, equine, porcine and primate) for conducting preclinical studies, accelerating the pace of drug discovery and development. With world-class infrastructure and expert support, the facility serves as a cornerstone of scientific excellence within GV.

Strategic Partnerships with Global Players

GV Research Platform (GVRP) headquartered in Genome Valley, has emerged as a rising star in the field of preclinical research for biomedical industry having formed strategic partnerships with global players like Crown Bioscience and Envigo (An Inotiv company) from the USA, Nexel (South Korea) and Senzagen (Sweden), offering a diverse range of cutting-edge high quality branded animal models and preclinical services. These kinds of collaborations facilitate knowledge exchange and technology transfer, driving synergies and fostering growth within the preclinical research community.

World-class Infrastructure for high quality services

India is witnessing a surge in biotechnology entrepreneurship, with numerous startups eager to venture into biosimilars and cutting-edge research. Platforms like the BHub accelerator, equipped with state-of-the-art facilities for bioprocess scale-up, provide them with ample opportunities to pioneer innovation. Additionally, access to top-notch drug discovery and development services through GV streamlines their path to achieving results swiftly and efficiently.

As we look to the future, the prospects for Genome Valley as Asia's premier preclinical research hub have never been brighter. With a dynamic ecosystem of companies, incubators (BTIC – Biotechnology Incubation Centre) accelerators (B-Hub), national institutes and research facilities, GV is poised to lead the way in addressing the complex challenges of preclinical research. 

Vishal Goel, Managing Director, Rx Propellant